Lesogaberan

DB11920InvestigationalSmall molecule

Lesogaberan has been used in trials studying the treatment and basic science of GERD, Reflux, Heartburn, Regurgitation, and Reflux Disease, among others.

Mechanism: Pharmacologically active on Gamma-aminobutyric acid type B receptor subunit 1 and Gamma-aminobutyric acid type B receptor subunit 2
Curator reviewed
Formula / weight: C₃H₉FNO₂P · 141.082 g/mol (avg)
Code names: AZD-3355

Resolves to

Compound

UNII4D6Q6HGC7ZCAS344413-67-8ChEMBLCHEMBL448343PubChem9833984

Structure

InChIKeyLJNUIEQATDYXJH-GSVOUGTGSA-NSMILESNC[C@@H](F)CP(O)=O

Targets

Q9UBS5GABBR1O75899GABBR2

What you can answer from here — as of August 27, 2024

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

8Clinical trialsPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Lesogaberan, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account